Baidu
map

PLoS ONE:转录组断层技术可对脑部疾病的基因表达进行三维成像

2013-01-14 T.Shen 生物谷

近日,来自日本一个研究小组开发出了一种新型技术,可以对大脑结构中的基因表达样式进行三维成像,这种技术俗称为转录组断层技术,其结合了组织切片的微阵列技术,可以都对脑部基因表达的密度和位置进行精确图谱成像,相比当前的绘图成像技术,这种新型技术具有较高的分辨率,相关研究成果发表于国际杂志PLoS ONE上。 为了产生最新的数据资料,研究者将6个小鼠大脑切割分为许多5微米的部分,并且将每一部分分为3个解

近日,来自日本一个研究小组开发出了一种新型技术,可以对大脑结构中的基因表达样式进行三维成像,这种技术俗称为转录组断层技术,其结合了组织切片的微阵列技术,可以都对脑部基因表达的密度和位置进行精确图谱成像,相比当前的绘图成像技术,这种新型技术具有较高的分辨率,相关研究成果发表于国际杂志PLoS ONE上。

为了产生最新的数据资料,研究者将6个小鼠大脑切割分为许多5微米的部分,并且将每一部分分为3个解剖平面,研究者将这些样品进行收集并且使用微阵列技术将其分为1毫米厚度的组织碎片,随后,研究者用36,000个RNA探针对61个组织碎片进行处理并且重建数据以产生贯穿整个小鼠大脑的基因表达3D图谱。

这种转录组断层技术是一种半自动基础,相比当前手动方法更为有效和快速,这种技术可以被用于进行任何类型生化分子的组织分布图谱的绘制,比如蛋白质、脂质、糖类以及microRNAs在组织中的分布图谱的绘制等。

研究者Okamura-Oho和其同事通过比较以前方法所获得的数据和现在所获得的数据,更加确定了这项新型技术,同时研究者也分析了亨廷顿疾病基因表达的样式,亨廷顿疾病是一种神经变性疾病,主要表现为基底神经节神经元的死亡,紧接着会引发患者大脑皮层细胞的死亡。

研究分析揭示了亨廷丁在大脑区域中处于高表达的水平,这样就会严重影响患者的状况,比如基底神经节,但是在亨廷丁较低水平的区域,影响就相对小些,比如在中脑和小脑区域。研究者表示,相比MRI,这种新技术可以使得表达图谱分辨率高达20倍以上,高分辨率的基因表达图谱就能够更加详细地揭示疾病相关的异常情况。

转录组断层扫描数据组可以被上传至Waxholm空间,这样就方便研究者们进行资源数据共享以及疾病研究相关的分析。

doi:10.1371/journal.pone.0045373
PMC:
PMID:

Transcriptome Tomography for Brain Analysis in the Web-Accessible Anatomical Space

Okamura-Oho Y, Shimokawa K, Takemoto S, Hirakiyama A, Nakamura S, et al.

Increased information on the encoded mammalian genome is expected to facilitate an integrated understanding of complex anatomical structure and function based on the knowledge of gene products. Determination of gene expression-anatomy associations is crucial for this understanding. To elicit the association in the three-dimensional (3D) space, we introduce a novel technique for comprehensive mapping of endogenous gene expression into a web-accessible standard space: Transcriptome Tomography. The technique is based on conjugation of sequential tissue-block sectioning, all fractions of which are used for molecular measurements of gene expression densities, and the block- face imaging, which are used for 3D reconstruction of the fractions. To generate a 3D map, tissues are serially sectioned in each of three orthogonal planes and the expression density data are mapped using a tomographic technique. This rapid and unbiased mapping technique using a relatively small number of original data points allows researchers to create their own expression maps in the broad anatomical context of the space. In the first instance we generated a dataset of 36,000 maps, reconstructed from data of 61 fractions measured with microarray, covering the whole mouse brain (ViBrism: http://vibrism.riken.jp/3dviewer/ex/inde​x.html) in one month. After computational estimation of the mapping accuracy we validated the dataset against existing data with respect to the expression location and density. To demonstrate the relevance of the framework, we showed disease related expression of Huntington’s disease gene and Bdnf. Our tomographic approach is applicable to analysis of any biological molecules derived from frozen tissues, organs and whole embryos, and the maps are spatially isotropic and well suited to the analysis in the standard space (e.g. Waxholm Space for brain-atlas databases). This will facilitate research creating and using open-standards for a molecular-based understanding of complex structures; and will contribute to new insights into a broad range of biological and medical questions.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2037396, encodeId=45ae203e39678, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 15 00:30:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747170, encodeId=d5e61e471708b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Dec 20 10:30:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937848, encodeId=a46f193e84815, content=<a href='/topic/show?id=476819e5803' target=_blank style='color:#2F92EE;'>#三维成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19758, encryptionId=476819e5803, topicName=三维成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jul 28 08:30:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789496, encodeId=4e0d1e894966c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 07 00:30:00 CST 2013, time=2013-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347989, encodeId=57f0134e989ff, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420155, encodeId=e6a8142015585, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2037396, encodeId=45ae203e39678, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 15 00:30:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747170, encodeId=d5e61e471708b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Dec 20 10:30:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937848, encodeId=a46f193e84815, content=<a href='/topic/show?id=476819e5803' target=_blank style='color:#2F92EE;'>#三维成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19758, encryptionId=476819e5803, topicName=三维成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jul 28 08:30:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789496, encodeId=4e0d1e894966c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 07 00:30:00 CST 2013, time=2013-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347989, encodeId=57f0134e989ff, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420155, encodeId=e6a8142015585, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
    2013-12-20 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=2037396, encodeId=45ae203e39678, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 15 00:30:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747170, encodeId=d5e61e471708b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Dec 20 10:30:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937848, encodeId=a46f193e84815, content=<a href='/topic/show?id=476819e5803' target=_blank style='color:#2F92EE;'>#三维成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19758, encryptionId=476819e5803, topicName=三维成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jul 28 08:30:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789496, encodeId=4e0d1e894966c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 07 00:30:00 CST 2013, time=2013-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347989, encodeId=57f0134e989ff, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420155, encodeId=e6a8142015585, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2037396, encodeId=45ae203e39678, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 15 00:30:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747170, encodeId=d5e61e471708b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Dec 20 10:30:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937848, encodeId=a46f193e84815, content=<a href='/topic/show?id=476819e5803' target=_blank style='color:#2F92EE;'>#三维成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19758, encryptionId=476819e5803, topicName=三维成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jul 28 08:30:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789496, encodeId=4e0d1e894966c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 07 00:30:00 CST 2013, time=2013-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347989, encodeId=57f0134e989ff, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420155, encodeId=e6a8142015585, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2037396, encodeId=45ae203e39678, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 15 00:30:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747170, encodeId=d5e61e471708b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Dec 20 10:30:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937848, encodeId=a46f193e84815, content=<a href='/topic/show?id=476819e5803' target=_blank style='color:#2F92EE;'>#三维成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19758, encryptionId=476819e5803, topicName=三维成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jul 28 08:30:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789496, encodeId=4e0d1e894966c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 07 00:30:00 CST 2013, time=2013-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347989, encodeId=57f0134e989ff, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420155, encodeId=e6a8142015585, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2037396, encodeId=45ae203e39678, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 15 00:30:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747170, encodeId=d5e61e471708b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Dec 20 10:30:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937848, encodeId=a46f193e84815, content=<a href='/topic/show?id=476819e5803' target=_blank style='color:#2F92EE;'>#三维成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19758, encryptionId=476819e5803, topicName=三维成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jul 28 08:30:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789496, encodeId=4e0d1e894966c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 07 00:30:00 CST 2013, time=2013-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347989, encodeId=57f0134e989ff, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420155, encodeId=e6a8142015585, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Jan 16 04:30:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]

相关资讯

2012年Cell发表的中国研究

据《中国科技期刊引证报告2012》统计,2002~2012年(截止11月1日)10年间,我国科技人员共发 表102.26万篇国际论文,排名世界第2;被引用665.34万次,排名世界第6。其中,药学与毒物学居世界第6,生物与生物化学居世界第8,微生物学 居世界第10位。此外,分子生物学与遗传学位居世界第12位,神经科学与行为学居世界第13位,临床医学仍保持世界第14位,精神病学与心理学居世界第

JNCI:肥胖激素或可成为胰腺癌治疗的靶点

研究人员报告指出,低水平的肥胖相关激素(脂联素)与胰腺癌风险增加相关。在一项病例对照试验研究中,波士顿哈弗大学Ying Bao博士(MD、ScD)和他的同事们发现,胰腺癌患者与其确诊前一年或更早时期相比,血液样本中的激素水平显着降低。 这种联系不受吸烟、糖尿病、体重指数和其他已知或不确定的胰腺癌的风险等因素的影响。Bao和他的同事们的报告被在线发表在国家癌症研究所的杂志上。他们总结道:此项研究结

JACC:心脏磁共振T1绘图或将成为指导性诊断

急性心肌梗死后发生的左室重构是一个突出的临床问题,尤其在合并糖尿病、大面积心梗或再灌注延迟的患者亚组中。一些临床前研究显示,心梗后的心肌重构是多种机制相互作用的结果,包括神经内分泌、微血管和大血管因素。但之前,尚缺乏在活体上重现这些过程的方法,我们对人体内心梗后心肌重构的理解有限。 随着心脏磁共振(CMR)技术的普及,临床工作者试图通过CMR技术的使用,在这个领域进行探索。CMR具有高精度和准确

Eur Heart J:房颤者中断用华法林 血栓栓塞风险升高

12月23日,丹麦学者在Eur Heart J发表的一项研究"Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation"表明,在房颤患者中,中断华法林治疗与治疗中断后前90天内的死亡或血栓-栓

BBA-Mol Basis Dis:姚永刚等母系遗传性高血压研究获进展

高血压病是严重危害人类健康的常见疾病,全世界的患病人数已接近10亿,每年有接近760万的患者死于该病。我国每年用于治疗高血压的医疗费高达360多亿元。因此,高血压病是全球亟待解决的重大公共卫生问题和社会问题。 近期,中国科学院昆明动物研究所博士后郭皓和庄馨瑛博士等在姚永刚研究员的指导下,对来自云南的一个母系遗传性高血压病家系进行了深入研究。为今后临床进行母系遗传性高血压病的遗传咨询、阐明其发病机

Stroke:变异EPO可以作为缺血性脑卒中药物干预的新选择

促红细胞生成素 (EPO) 对缺血性损伤有神经保护作用。但是,EPO治疗卒中时需要大剂量并多次给药,这样会因它的促红细胞生成作用产生严重的副作用。匹兹堡大学的Guodong Cao博士等人研究发现:变异的EPO能够保留神经保留作用,但没有促红细胞生成活性及激活血小板的活性。可以作为卒中临床干预的选择。 研究人员制备了一系列的变异EPO, 每种都只改变EPO模序中的一个氨基酸,测定它们的促红细胞生

Baidu
map
Baidu
map
Baidu
map